Scientific publications

October 2025
First-in-Human Study of the First-in-Class Non-cellular Targeting Antibody-Drug Conjugate (ADC), Micvotabart Pelidotin (MICVO), in Patients With Select Solid Tumors – Abstract Number: 965
ESMO Poster
October 2025
Longitudinal changes in circulating tumor DNA in a phase 1 dose escalation study of micvotabart pelidotin, a first-in-human ADC targeting EDB+FN – Abstract Number: 1004
ESMO Poster
October 2025
Validation of anti-ADC assays with ADA Characterization to support Micvotabart Pelidotin Clinical Studies – P15
The Immunogenicity & Bioassay Summit Poster
October 2025
Anti-tumor activity of micvotabart pelidotin is associated with enzyme gene expression in patient-derived xenograft sarcoma models – Abstract: 2165379
CTOS Poster
April 2025
The combination of anti-PD1 and a mouse analog of PYX-201, an antibody-drug conjugate targeting the extra-domain B splice variant of fibronectin (EDB+FN), shows greater anti-tumor efficacy than either treatment alone – Abstract Number: 3137
AACR Poster
April 2025
Evaluation of PYX-201, an EDB+FN-targeting ADC, in a comprehensive PDX mini-trial study enables identification of gene signatures associated with anti-tumor activity – Abstract Number: 3120
AACR Poster
November 2024
Sarcomas express extra domain B of fibronectin and preclinical patient-derived xenograft models of several sarcoma subtypes are sensitive to the stroma targeting antibody drug conjugate PYX-201 – Abstract #: 1854935
CTOS Poster
November 2024
Associations of the immunomodulatory molecule Siglec-15 gene and protein expression to immune gene signatures as a potential biomarker for Siglec-15 targeted therapy in non-small cell lung cancer – Abstract #: 219
SITC Poster
November 2024
Characterization and prevalence of the novel immunomodulatory protein Siglec-15 expression in tumor cells and macrophages across multiple solid tumor indications – Abstract # 521
SITC Poster
November 2024
PYX-106, a highly differentiated anti-Siglec-15 monoclonal antibody, reverses Siglec-15 mediated immune suppression and enhances cytotoxic activity in human lymphocytes – Abstract #: 567
SITC Poster